Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives
Diabetes mellitus (DM) and pancreatic neuroendocrine tumors (pNETs) are two entities closely linked together. DM has been described as a risk factor for the development of pNETs and for the aggressiveness of the disease. On the other hand, DM due to pNETs is frequently undiagnosed or misclassified a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/12/11/1103 |
| _version_ | 1797464581127274496 |
|---|---|
| author | Lorena Hernandez-Rienda Maria Isabel del Olmo-García Juan Francisco Merino-Torres |
| author_facet | Lorena Hernandez-Rienda Maria Isabel del Olmo-García Juan Francisco Merino-Torres |
| author_sort | Lorena Hernandez-Rienda |
| collection | DOAJ |
| description | Diabetes mellitus (DM) and pancreatic neuroendocrine tumors (pNETs) are two entities closely linked together. DM has been described as a risk factor for the development of pNETs and for the aggressiveness of the disease. On the other hand, DM due to pNETs is frequently undiagnosed or misclassified as type 2 DM when it is due to type 3 DM. In addition, metformin, a commonly prescribed drug for type 2 DM, has an antiproliferative property and is gaining increasing attention as an antitumor agent. This review article presents the findings published in the last few years on pNETs and DMs. Emphasis will be placed on DM as a risk factor, pNET as a risk factor for the development of type 3 DM, the management of type 3 DM on pNET, and DM as a prognostic factor in patients with pNET, as well as the future clinical implications of DM in these patients. The coexistence of DM and pNET is extensively presented. It is important to perform future clinical trials, which are necessary to establish the role of metformin on pNET disease. Increasing awareness among professionals managing pNET on the importance of a correct DM diagnosis and management of the disease must be a priority due to the implications on mortality and comorbidities it may have in these patients. |
| first_indexed | 2024-03-09T18:09:12Z |
| format | Article |
| id | doaj.art-bb3e06d33a85408bb3cad0443c71abe5 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T18:09:12Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-bb3e06d33a85408bb3cad0443c71abe52023-11-24T09:13:03ZengMDPI AGMetabolites2218-19892022-11-011211110310.3390/metabo12111103Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future PerspectivesLorena Hernandez-Rienda0Maria Isabel del Olmo-García1Juan Francisco Merino-Torres2Endocrinology and Nutrition Department, University and Politecnic Hospital La Fe, 46026 Valencia, SpainEndocrinology and Nutrition Department, University and Politecnic Hospital La Fe, 46026 Valencia, SpainEndocrinology and Nutrition Department, University and Politecnic Hospital La Fe, 46026 Valencia, SpainDiabetes mellitus (DM) and pancreatic neuroendocrine tumors (pNETs) are two entities closely linked together. DM has been described as a risk factor for the development of pNETs and for the aggressiveness of the disease. On the other hand, DM due to pNETs is frequently undiagnosed or misclassified as type 2 DM when it is due to type 3 DM. In addition, metformin, a commonly prescribed drug for type 2 DM, has an antiproliferative property and is gaining increasing attention as an antitumor agent. This review article presents the findings published in the last few years on pNETs and DMs. Emphasis will be placed on DM as a risk factor, pNET as a risk factor for the development of type 3 DM, the management of type 3 DM on pNET, and DM as a prognostic factor in patients with pNET, as well as the future clinical implications of DM in these patients. The coexistence of DM and pNET is extensively presented. It is important to perform future clinical trials, which are necessary to establish the role of metformin on pNET disease. Increasing awareness among professionals managing pNET on the importance of a correct DM diagnosis and management of the disease must be a priority due to the implications on mortality and comorbidities it may have in these patients.https://www.mdpi.com/2218-1989/12/11/1103neuroendocrine tumorsdiabetes mellitustype 3 diabetesmetformin |
| spellingShingle | Lorena Hernandez-Rienda Maria Isabel del Olmo-García Juan Francisco Merino-Torres Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives Metabolites neuroendocrine tumors diabetes mellitus type 3 diabetes metformin |
| title | Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives |
| title_full | Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives |
| title_fullStr | Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives |
| title_full_unstemmed | Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives |
| title_short | Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives |
| title_sort | impact of diabetes mellitus in patients with pancreatic neuro endocrine tumors causes consequences and future perspectives |
| topic | neuroendocrine tumors diabetes mellitus type 3 diabetes metformin |
| url | https://www.mdpi.com/2218-1989/12/11/1103 |
| work_keys_str_mv | AT lorenahernandezrienda impactofdiabetesmellitusinpatientswithpancreaticneuroendocrinetumorscausesconsequencesandfutureperspectives AT mariaisabeldelolmogarcia impactofdiabetesmellitusinpatientswithpancreaticneuroendocrinetumorscausesconsequencesandfutureperspectives AT juanfranciscomerinotorres impactofdiabetesmellitusinpatientswithpancreaticneuroendocrinetumorscausesconsequencesandfutureperspectives |